About UCB Pharmaceuticals
UCB is a global biopharmaceutical leader with headquarters in Brussels, Belgium. It combines the global infrastructure and expertise of a traditional Pharma company with the speed, innovation and entrepreneurship of a biotech company. UCB employs over 8,500 people operating in over 40 countries worldwide. UCB achieved revenues of € 1.2 billion in 1st half 2005 - (up 11%) versus the same period last year - with a net profit from continuing operations amounting to € 165 million for the same period - (up 16%).
Mission
To provide novel therapeutic solutions for patients with severe diseases treated by specialists, particularly in the fields of central nervous system disorders (including epilepsy), inflammatory disorders (including allergy) and oncology. UCB's medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Product Overview:
Central Nervous System
Vimpat® (lacosamide)
Epilepsy
Keppra® (levetiracetam)
Epilepsy
Neupro® (rotigotine)
Parkinson's disease
Restless Legs Syndrome
Nootropil® (piracetam)
Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII)
Attention Deficit Hyperactivity Disorder (ADHD)
Immunology
Cimzia® (certolizumab pegol)
Crohn's disease
Rheumatoid arthritis
Xyzal® (levocetirizine)
Allergies
Zyrtec® (cetirizine)
Allergies
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII)
Respiratory disease
